← Back to Clinical Trials
Recruiting NCT02996656

NCT02996656 Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02996656
Status Recruiting
Phase
Sponsor Université de Montréal
Condition Propionibacterium Infection
Study Type INTERVENTIONAL
Enrollment 88 participants
Start Date 2016-12
Primary Completion 2026-12

Trial Parameters

Condition Propionibacterium Infection
Sponsor Université de Montréal
Study Type INTERVENTIONAL
Phase N/A
Enrollment 88
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2016-12
Completion 2026-12
Interventions
CefazolinCeftriaxone

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. With the increasing rate of identified P. acnes shoulder surgery infection despite the use of recommended skin preparation and preoperative prophylactic antibiotics, a question arises; Is Cefazolin the most effective prophylactic antibiotic for shoulder surgery? The objective of this study is to determine if Ceftriaxone is superior to Cefazolin as a prophylactic antibiotic for skin colonization with P. acnes in primary shoulder surgery

Eligibility Criteria

Inclusion Criteria: * 18 years and older * Male or female * Presenting normal skin on the shoulder aria Exclusion Criteria: * Used antibiotics or treated their skin with antibiotic gel, alcohol gel or cream or acne treatment in the last three months * Active infection at the surgical site or anywhere * Affected shoulder previously received radiotherapy * Allergic to one of the antimicrobial prophylaxis used * Open fracture * Life threatening or a limb threatening pathology * Liver or kidney failure

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology